HAP Trading’s Amylyx Pharmaceuticals AMLX Stock Holding History

HAP Trading’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-50,000	Closed	-$55K	–	680
2024 Q2	$55K	Hold	50,000	–	–	0.01%	438
2024 Q1	$36.3K	Buy	+50,000	New	+$654K	﹤0.01%	464

Other funds holding AMLX

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HAP Trading's AMLX Position: Q3 2022 in Review

HAP Trading sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2022, closing a stake of 15,322 shares — an estimated $382K sold.

HAP Trading first reported a position in AMLX in Q2 2022 and held it in 1 quarter. The position peaked at $295K in Q2 2022. 95 funds tracked by Wall St. Rank hold AMLX as of Q3 2022.

HAP Trading reported no remaining Amylyx Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
HAP Trading sold 15,322 Amylyx Pharmaceuticals shares in Q3 2022, an estimated $382K.
HAP Trading first reported a position in Amylyx Pharmaceuticals in Q2 2022 and held it in 1 quarter.
HAP Trading's Amylyx Pharmaceuticals position peaked at $295K in Q2 2022.
95 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2022.

Based on HAP Trading's 13F filing for Q3 2022, filed 14 Nov 2022.